Neurocrine says Indiplon may need more testing
The company developing Indiplon says federal regulators may require additional clinical tests before approving the experimental insomnia drug.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.